Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMT8Y65)

Drug Name
ASIATIC ACID Drug Info
Synonyms
Asiatic acid; 464-92-6; Dammarolic acid; UNII-9PA5A687X5; NSC 166063; CHEBI:2873; CHEMBL404313; JXSVIVRDWWRQRT-UYDOISQJSA-N; 9PA5A687X5; Asiantic acid; (1S,2R,4aS,6aR,6aS,6bR,8aR,9R,10R,11R,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid; Asiatic-acid; MFCD00238541; HSDB 7662; NSC-166063; 2,3,23-trihydroxyurs-12-en-28-oic acid; A)-2,3,23-trihydroxyurs-12-en-28-oic acid; Asiatic acid, 97%; AC1Q5QHS; AC1L3O2W
Cross-matching ID
PubChem CID
119034
ChEBI ID
CHEMBL404313
CAS Number
CAS 464-92-6
TTD Drug ID
D0LC7K

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Graft-versus-host disease 2.21 0.00e+0 32/42 (76.19%) PRF1;GZMB;IFNG;...
NF-kappa B signaling pathway 2.14 5.45e-3 90/104 (86.54%) CCL4;CD14;GADD45G;...
Pertussis 2.11 3.64e-3 64/76 (84.21%) C1QA;C1QB;ITGAM;...
Viral protein interaction with cytokine and cytokine re... 2.09 2.73e-3 84/100 (84%) CXCL13;CCL4;CCL5;...
Toll-like receptor signaling pathway 2.06 2.18e-3 94/104 (90.38%) CCL4;CCL5;CD14;...
Allograft rejection 2.06 1.82e-3 32/38 (84.21%) PRF1;GZMB;IFNG;...
Natural killer cell mediated cytotoxicity 2.05 1.56e-3 99/131 (75.57%) KLRK1;CD48;PRF1;...
Cytosolic DNA-sensing pathway 2.05 1.36e-3 52/63 (82.54%) CCL4;CCL5;AIM2;...
Rheumatoid arthritis 2.04 1.21e-3 78/93 (83.87%) CCL5;ATP6V1D;LTB;...
Legionellosis 2.03 1.09e-3 51/57 (89.47%) ITGAM;CD14;CXCL1;...
Leishmaniasis 2.02 9.92e-4 67/77 (87.01%) ITGAM;NCF4;TLR4;...
Inflammatory bowel disease 1.99 9.09e-4 58/65 (89.23%) STAT4;TLR4;IFNG;...
Chemokine signaling pathway 1.96 1.68e-3 163/192 (84.9%) CXCL13;CCL4;CCL5;...
Cytokine-cytokine receptor interaction 1.94 1.56e-3 246/295 (83.39%) CXCL13;CCL4;CCL5;...
Fc epsilon RI signaling pathway 1.88 2.91e-3 57/68 (83.82%) ALOX5AP;ALOX5;LCP2;...
TNF signaling pathway 1.82 4.77e-3 103/112 (91.96%) CCL5;LIF;CXCL1;...
C-type lectin receptor signaling pathway 1.82 4.49e-3 93/104 (89.42%) NFATC3;ARHGEF12;RHOA;...
Systemic lupus erythematosus 1.80 7.88e-3 45/135 (33.33%) C1QA;C1QB;FCGR3B;...
Asthma 1.78 7.46e-3 25/31 (80.65%) TNF;HLA-DRA;HLA-DPA1;...
Autoimmune thyroid disease 1.77 8.18e-3 46/53 (86.79%) PRF1;GZMB;HLA-DRA;...
Hematopoietic cell lineage 1.77 8.31e-3 90/99 (90.91%) CD8A;ITGAM;CD14;...
IL-17 signaling pathway 1.77 7.93e-3 84/94 (89.36%) CXCL1;CXCL2;IFNG;...
Th1 and Th2 cell differentiation 1.75 9.49e-3 80/92 (86.96%) IL2RB;RUNX3;STAT4;...
Type I diabetes mellitus 1.74 1.27e-2 38/43 (88.37%) PRF1;GZMB;IFNG;...
Th17 cell differentiation 1.73 1.27e-2 95/107 (88.79%) IL2RB;NFATC3;IFNG;...
Tuberculosis 1.71 1.59e-2 159/180 (88.33%) ITGAM;CD14;TLR4;...
Malaria 1.71 1.62e-2 44/50 (88%) KLRK1;TLR4;IFNG;...
Staphylococcus aureus infection 1.70 1.75e-2 72/95 (75.79%) C1QA;C1QB;ITGAM;...
T cell receptor signaling pathway 1.67 1.88e-2 93/104 (89.42%) CD8A;NFATC3;CD8B;...
Fc gamma R-mediated phagocytosis 1.65 2.47e-2 79/97 (81.44%) BIN1;MARCKS;FCGR3B;...
Arginine and proline metabolism -1.65 4.80e-2 39/50 (78%) SAT1;GAMT;AOC1;...
Thyroid hormone synthesis -1.68 3.98e-2 66/75 (88%) TG;DUOX2;ADCY8;...
Pancreatic secretion -1.73 2.84e-2 87/102 (85.29%) RAP1B;PRSS1;ADCY8;...
Other glycan degradation -1.75 2.57e-2 13/18 (72.22%) ENGASE;MAN2B2;HEXA;...
Renin-angiotensin system -1.78 1.84e-2 20/23 (86.96%) KLK2;PRCP;ENPEP;...
Fat digestion and absorption -1.79 1.95e-2 35/43 (81.4%) MTTP;DGAT1;PLA2G1B;...
Tryptophan metabolism -1.80 1.97e-2 35/42 (83.33%) DHTKD1;CYP1A1;HADHA;...
Retinol metabolism -1.83 1.84e-2 41/68 (60.29%) ADH6;BCO1;CYP26A1;...
Steroid biosynthesis -1.83 2.02e-2 19/20 (95%) EBP;CYP27B1;HSD17B7;...
Pentose and glucuronate interconversions -1.84 2.07e-2 17/34 (50%) CRYL1;SORD;UGT2B17;...
Glyoxylate and dicarboxylate metabolism -1.98 6.12e-3 23/30 (76.67%) PCCA;PCCB;HYI;...
Proximal tubule bicarbonate reclamation -2.11 4.59e-3 21/23 (91.3%) GLUD1;CA2;ATP1A2;...
Mineral absorption -2.23 0.00e+0 48/60 (80%) CLCN2;SLC26A3;ATP1A2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.25uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.25uM - 10uM 6H, 24H